Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Aging in the mouse and perspectives of rejuvenation through induced pluripotent stem cells (iPSCs).

Isobe K, Cheng Z, Ito S, Nishio N.

Results Probl Cell Differ. 2012;55:413-27. doi: 10.1007/978-3-642-30406-4_21. Review.

PMID:
22918818
2.

Establishment of induced pluripotent stem cells from aged mice using bone marrow-derived myeloid cells.

Cheng Z, Ito S, Nishio N, Xiao H, Zhang R, Suzuki H, Okawa Y, Murohara T, Isobe K.

J Mol Cell Biol. 2011 Apr;3(2):91-8. doi: 10.1093/jmcb/mjq044. Epub 2011 Jan 12.

PMID:
21228011
3.

Generation of stable pluripotent stem cells from NOD mouse tail-tip fibroblasts.

Liu J, Ashton MP, Sumer H, O'Bryan MK, Brodnicki TC, Verma PJ.

Diabetes. 2011 May;60(5):1393-8. doi: 10.2337/db10-1540. Epub 2011 Apr 4.

4.

Optimal reprogramming factor stoichiometry increases colony numbers and affects molecular characteristics of murine induced pluripotent stem cells.

Tiemann U, Sgodda M, Warlich E, Ballmaier M, Schöler HR, Schambach A, Cantz T.

Cytometry A. 2011 Jun;79(6):426-35. doi: 10.1002/cyto.a.21072. Epub 2011 May 4.

5.

iPSCs, aging and age-related diseases.

Isobe K, Cheng Z, Nishio N, Suganya T, Tanaka Y, Ito S.

N Biotechnol. 2014 Sep 25;31(5):411-21. doi: 10.1016/j.nbt.2014.04.004. Epub 2014 Apr 29.

PMID:
24784583
6.

From skin to the treatment of diseases--the possibilities of iPS cell research in dermatology.

Galach M, Utikal J.

Exp Dermatol. 2011 Jun;20(6):523-8. doi: 10.1111/j.1600-0625.2011.01282.x. Review.

PMID:
21585557
7.

Generation of induced pluripotent stem cells from human adipose-derived stem cells without c-MYC.

Aoki T, Ohnishi H, Oda Y, Tadokoro M, Sasao M, Kato H, Hattori K, Ohgushi H.

Tissue Eng Part A. 2010 Jul;16(7):2197-206. doi: 10.1089/ten.TEA.2009.0747.

PMID:
20146561
8.

Generation of induced pluripotent stem cells in rabbits: potential experimental models for human regenerative medicine.

Honda A, Hirose M, Hatori M, Matoba S, Miyoshi H, Inoue K, Ogura A.

J Biol Chem. 2010 Oct 8;285(41):31362-9. doi: 10.1074/jbc.M110.150540. Epub 2010 Jul 29.

9.

Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells.

Zhou W, Freed CR.

Stem Cells. 2009 Nov;27(11):2667-74. doi: 10.1002/stem.201.

10.

Generation of mice derived from induced pluripotent stem cells.

Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Martin G, Kupriyanov S, Baldwin KK.

J Vis Exp. 2012 Nov 29;(69):e4003. doi: 10.3791/4003.

11.

Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery.

Jang J, Yoo JE, Lee JA, Lee DR, Kim JY, Huh YJ, Kim DS, Park CY, Hwang DY, Kim HS, Kang HC, Kim DW.

Exp Mol Med. 2012 Mar 31;44(3):202-13. doi: 10.3858/emm.2012.44.3.015.

12.

Crucial role of c-Myc in the generation of induced pluripotent stem cells.

Araki R, Hoki Y, Uda M, Nakamura M, Jincho Y, Tamura C, Sunayama M, Ando S, Sugiura M, Yoshida MA, Kasama Y, Abe M.

Stem Cells. 2011 Sep;29(9):1362-70. doi: 10.1002/stem.685.

13.

Self-renewal and pluripotency acquired through somatic reprogramming to human cancer stem cells.

Nagata S, Hirano K, Kanemori M, Sun LT, Tada T.

PLoS One. 2012;7(11):e48699. doi: 10.1371/journal.pone.0048699. Epub 2012 Nov 8.

14.

Genetic background affects induced pluripotent stem cell generation.

Schnabel LV, Abratte CM, Schimenti JC, Southard TL, Fortier LA.

Stem Cell Res Ther. 2012 Aug 3;3(4):30. doi: 10.1186/scrt121.

15.

An improved method for the derivation of high quality iPSCs in the absence of c-Myc.

Habib O, Habib G, Choi HW, Hong KS, Do JT, Moon SH, Chung HM.

Exp Cell Res. 2013 Dec 10;319(20):3190-200. doi: 10.1016/j.yexcr.2013.09.014. Epub 2013 Oct 2.

PMID:
24095950
16.

Derivation of induced pluripotent stem cells by retroviral gene transduction in mammalian species.

Imamura M, Okuno H, Tomioka I, Kawamura Y, Lin ZY, Nakajima R, Akamatsu W, Okano HJ, Matsuzaki Y, Sasaki E, Okano H.

Methods Mol Biol. 2012;925:21-48. doi: 10.1007/978-1-62703-011-3_2.

PMID:
22907488
17.

Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells.

Griscelli F, Féraud O, Oudrhiri N, Gobbo E, Casal I, Chomel JC, Biéche I, Duvillard P, Opolon P, Turhan AG, Bennaceur-Griscelli A.

Am J Pathol. 2012 May;180(5):2084-96. doi: 10.1016/j.ajpath.2012.01.011. Epub 2012 Mar 13.

PMID:
22425713
18.

Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state.

Lapasset L, Milhavet O, Prieur A, Besnard E, Babled A, Aït-Hamou N, Leschik J, Pellestor F, Ramirez JM, De Vos J, Lehmann S, Lemaitre JM.

Genes Dev. 2011 Nov 1;25(21):2248-53. doi: 10.1101/gad.173922.111.

19.

Differentiation efficiency of induced pluripotent stem cells depends on the number of reprogramming factors.

Löhle M, Hermann A, Glass H, Kempe A, Schwarz SC, Kim JB, Poulet C, Ravens U, Schwarz J, Schöler HR, Storch A.

Stem Cells. 2012 Mar;30(3):570-9. doi: 10.1002/stem.1016.

20.

Expansion and long-term maintenance of induced pluripotent stem cells in stirred suspension bioreactors.

Shafa M, Sjonnesen K, Yamashita A, Liu S, Michalak M, Kallos MS, Rancourt DE.

J Tissue Eng Regen Med. 2012 Jun;6(6):462-72. doi: 10.1002/term.450. Epub 2011 Jul 14.

PMID:
21761573

Supplemental Content

Support Center